Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days' LMP: A prospective comparative open-label trial
Contraception, Volume 89, No. 3, Year 2014
Notification
URL copied to clipboard!
Description
Objective To test the effectiveness and acceptability of an outpatient medical abortion protocol with 200 mg mifepristone and 400 mcg sublingual misoprostol at 64-70 days' last menstrual period (LMP) and compare it to the already known efficacy of the 57-63 days' LMP gestational age range. Study Design We conducted a prospective, comparative open-label trial in six hospitals and clinics in Ukraine, Georgia, India and Tunisia. We enrolled 714 reproductive age women with pregnancies 57 to 70 days who presented requesting abortion. Medical abortions were managed with the current service delivery protocol (200 mg oral mifepristone followed in 24-48 h by 400 mcg sublingual misoprostol). Data on safety, efficacy and acceptability were collected. The main outcome measure was complete abortion without surgical intervention at any point. Results A total of 703 cases were analyzable for efficacy. Success rates did not differ significantly in the two groups [57-63-day group: 94·8%; 64-70-day group: 91.9%; Relative Risk (RR): 0.79 (0.61-1.04)]. Ongoing pregnancy rates also did not differ significantly (57-63 days: 1.8%; 64-70 days: 2.2%; RR: 1.10 (0.65-1.87)]. Conclusion A medical abortion regimen of 200 mg mifepristone followed in 24-48 h by 400 mcg sublingual misoprostol is effective through 70 days' gestation and may be offered within existing outpatient abortion services. Implications A regimen of 200 mg mifepristone followed in 24-48 h by 400 mcg sublingual misoprostol is effective up to 70 days' LMP. The findings have important implications for expanding access to outpatient medical abortion services in settings where the cost of misoprostol is of concern or a two-pill misoprostol regimen is the standard of care. © 2014 The Authors. Published by Elsevier Inc. All rights reserved.
Authors & Co-Authors
Bracken, Hillary
United States, New York
Gynuity Health Projects
Dabash, Rasha
United States, New York
Gynuity Health Projects
Tsertsvadze, George
Georgia, Tbilisi
Zhordania Institute of Human Reproduction
Posohova, Svetlana
Ukraine, Odessa
Central District Maternity House
Shah, Milind
India, Solapur
Naval Maternity and Nursing Home
Hajri, Selma
Tunisia, Tunis
Reproductive Health Consultant
Mundle, Shuchita Ramesh
India, Nagpur
Government Medical College Nagpur
Chélli, Héla
Tunisia, Tunis
Hôpital la Rabta
Zeramdini, Dhouha
Tunisia, Nabeul
Family Planning Center of Nabeul
Tsereteli, Tamar
Georgia, Tbilisi
Gynuity Health Projects
Platais, Ingrida
United States, New York
Gynuity Health Projects
Winikoff, Beverly
United States, New York
Gynuity Health Projects
Statistics
Citations: 42
Authors: 12
Affiliations: 9
Identifiers
Doi:
10.1016/j.contraception.2013.10.018
ISSN:
00107824
e-ISSN:
18790518
Research Areas
Health System And Policy
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Randomised Control Trial
Cohort Study
Study Locations
Tunisia
Participants Gender
Female